In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.